All In Biotech

Drug Trial Radar · NCT02651662

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

105

Actual

Start

Jan 11, 2016

Primary completion

Apr 29, 2026

Study completion Apr 29, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

Conditions

  • Relapsed/Refractory Aggressive B-Cell Lymphoma

Interventions

  • cemiplimabDrug

    Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.

  • odronextamabDrug

    Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) of cemiplimab in combination with odronextamabTime frame: Up to 28 days
  2. Incidence of treatment emergent adverse events (TEAEs) of cemiplimab in combination with odronextamabTime frame: Up to 18 months
  3. Severity of TEAEs of cemiplimab in combination with odronextamabTime frame: Up to 18 months
  4. Incidence of adverse events of special interest (AESIs) of cemiplimab in combination with odronextamabTime frame: Up to 18 months
  5. Severity of AESIs of cemiplimab in combination with odronextamabTime frame: Up to 18 months

Locations

30 sites in 6 countries. Site status is shown where the registry gives one.

  • Johns Hopkins University

    Baltimore, Maryland

  • Dana Farber/Harvard Cancer Center - PO box 849168

    Boston, Massachusetts

  • Harvard Medical School - Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III

    Salzburg, Austria

  • Medical University Vienna

    Vienna, Austria

  • University Hospital Frankfurt

    Frankfurt am Main, Germany

  • Universitatsklinikum Jena

    Jena, Germany

  • Universitatsklinikum Schleswig-Holstein, Campus Kiel

    Kiel, Germany

  • Soroka

    Beersheba, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Pratia Onkologia Katowice

    Katowice, Poland

  • Copernicus Memorial Hospital

    Lodz, Poland

  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa

    Warsaw, Poland

  • Pratia MCM Krakow

    Krakow, Malopolska, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Pomeranian Voivodeship, Poland

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Institut Catala dOncologia (ICO Hospitalet)

    Barcelona, Spain

  • MD Anderson Cancer Center- Madrid

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Clinico Universitario de Salamanca

    Salamanca, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain

  • Hospital Universitario Puerta de Hierro - Majadahonda

    Majadahonda, Madrid, Spain

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.